Liver transplantation for hepatocellular carcinoma (HCC) is the best treatment option for
patients with early-stage tumours and accounts for∼ 20–40% of all liver transplantations …

Effective immunosupression management is central to achieving optimal outcomes in liver
transplant recipients. Current immunosuppression regimens and agents are highly effective …

The first human orthotopic liver transplantation (LT) in Europe was performed by Sir Roy
Calne in Cambridge in 1968 [1], only one year after the first successful human liver …

Objective: The aim of this study was to evaluate the survival benefit of sirolimus in patients
undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC)(exploratory …

Background We investigated whether sirolimus-based immunosuppression improves
outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC) …

The optimal level of immunosuppression in solid organ transplantation, in particular for the
liver, is a delicate balance between the benefit of preventing rejection and the adverse side …

Hepatocellular carcinoma (HCC) is rapidly becoming one of the most prevalent cancers
worldwide. With a rising rate, it is a prominent source of mortality. Patients with advanced …

Hepatitis C virus (HCV) is one of the major aetiologic agents that causes hepatocellular
carcinoma (HCC) by generating an inflammatory, fibrogenic, and carcinogenic tissue …

Background & Aims Recurrence of hepatocellular carcinoma (HCC) is a major complication
after liver transplantation (LT). The initial immunosuppression protocol may influence HCC …

Liver transplantation is the best treatment option for cirrhotic patients with early-stage
hepatocellular carcinoma, but it faces the problem of scarcity of donors and the risk of tumor …